Neurol. praxi. 2010;11(3):201-203

What subanalysis of the ECASS III study results revealed

doc.MUDr.Roman Herzig, Ph.D., FESO

Neurologická klinika LF UP a FN, Olomouc

Randomized, placebo-controlled European Cooperative Acute Stroke Study III proved the safety and efficacy on the intravenous

thrombolysis (IVT) with recombinant tissue plasminogen activator (rt-PA) between 3 and 4.5 hours after the onset of ischemic stroke.

Subanalysis of the results of this study showed that the following significantly better results were more frequent in rt-PA treated

patients when compared to placebo: functional independence, defined as modified Rankin scale (mRS) score of 0–2 after 90 days

and, after 30 days, improvement of 8 points on the National Institutes of Health stroke scale (NIHSS) or achieving a score of 0–1 on the

NIHSS, Barthel index (BI) score of ≥ 95, mRS score of 0–1 and global outcome statistic. The use of the IVT with rt-PA in the extended

time window within 4.5 hours since the onset of ischemic stroke may be recommended in all patients, fulfilling the criteria for its

administration within 3 hours.

Keywords: intravenous thrombolysis, recombinant tissue plasminogen activator, ECASS III

Published: June 1, 2010  Show citation